Introduction {#sec1}
============

The human *XPC* (xeroderma pigmentosum complementation group C) gene is located on chromosome 3p25 and contains 16 exons and 15 introns \[[@B1],[@B2]\]. The human XPC protein with 940 amino acids, encoded by *XPC*, serves as an essential member within the NER (nucleotide excision repair) pathway \[[@B3]\]. The XPC protein is important for the early damage site recognition and DNA repair initiation of NER \[[@B3],[@B6],[@B7]\]. The abnormal expression of the XPC protein was also reportedly linked to the progression of the cancer \[[@B3],[@B8]\].

Within the *XPC* gene, three common variants, including rs2228000 (C21151T) of exon 8, rs2228001 (A33512C) of exon 15, and poly-AT insertion/deletion polymorphism (PAT^−/+^) of intron 9, were identified \[[@B4],[@B9]\]. *XPC* rs2228000 results in a substitution of alanine for valine in position 499 (Ala499Val), while rs2228001 leads to a transversion from lysine to glutamine in position 939 (Lys939Gln) \[[@B4],[@B9]\]. The present study investigated the potential genetic role of nonsynonymous *XPC* rs2228000 in the risk of different clinical types of cancer by pooling published studies with inconclusive conclusions.

After retrieving these studies, only three previous meta-analyses with no more than 15 studies in 2008 \[[@B12]\] and one meta-analysis with 33 studies in 2013 \[[@B15]\] were performed to assess the genetic association of *XPC* rs2228000 and the risk of overall cancer. Thus, we enrolled more sample sizes (71 case--control studies) and utilized different analysis strategies for an updated comprehensive evaluation in 2019 through meta-analysis and TSA (trial sequential analysis).

Materials and methods {#sec2}
=====================

Case--control study identification {#sec2-1}
----------------------------------

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) was utilized for our pooling analysis. In September 2019, we used a series of search terms (shown in Supplementary Table S1) to retrieve from four databases \[PubMed, Embase, CChia National Knowledge Infrastructure (CNKI)) and WOS (Web of Science)\] to obtain potentially relevant articles. We also designed a group of criteria for the inclusion/exclusion and eligibility assessment of the article. Inclusion criteria were the following: (1) case/control studies; (2) cancer; (3) *XPC* rs2228000; and (4) genotypic frequency data within both the case and control groups. Exclusion criteria were the following: (1) review; (2) meeting abstract; (3) case reports or family data; (4) meta-analysis; (5) cell, mice, horse, or other species; (6) other gene, disease or variant; (7) lack of specific data; (8) lack of normal group; (9) not in line with HWE (Hardy--Weinberg equilibrium); and (10) cohort.

Basic information collection {#sec2-2}
----------------------------

We extracted some basic information, including author name, publication year, country, race, genotypic frequency, cancer type, control source, genotyping assay, and sample size, from the selected eligible case--control studies. The *P*-value of HWE based on the genotypic distribution in the control group was calculated.

Article quality assessment {#sec2-3}
--------------------------

We utilized two approaches, including the NOS (Newcastle--Ottawa quality assessment scale) system (Supplementary Table S2) \[[@B16],[@B17]\] and the risk-of-bias score system (Supplementary Table S3) \[[@B18],[@B19]\] for the assessment of article quality. The article with an NOS score \> 5 and a risk-of-bias score \> 9 was considered to be high quality.

Pooling analysis {#sec2-4}
----------------

We used STATA software (Stata Corporation, U.S.A.) to perform the association test in the overall and subgroup meta-analysis, heterogeneity assessment, Begg's/Egger's tests (for the publication bias evaluation) and sensitivity analysis (for data stability assessment) \[[@B16],[@B17]\]. The OR (odds ratio), 95% CI (confidence interval) and *P*-value in a series of association tests under the five genetic models, including T vs. C (allele), TT vs. CC (homozygote), CT vs. CC (heterozygote), CT+TT vs. CC (dominant), and TT vs. CC+CT (recessive), were obtained. In addition, six factors, including race, country, control source, article quality, genotyping assay, and cancer type, were considered in our subgroup analysis.

The high heterogeneity was considered when the *I^2^* value in the *I^2^* test was larger than 50% and the *P*-value in the Q statistical test was less than 0.05, which led to the use of the DerSimonian--Laird method of the random-effect model. If not, a Mantel--Haenszel method of a fixed-effect model was used for the relatively low heterogeneity between studies.

False-positive report probability {#sec2-5}
---------------------------------

Targeting the positive findings, we also calculated the false-positive report probability (FPRP) and statistical power, as suggested by Wacholder et al. \[[@B20]\]. During analysis, an FPRP cut-off value of 0.2, a power OR of 1.5, and different prior probability levels (0.25, 0.1, 0.01, 0.001, 0.0001) were established. After assessing the research status regarding the association between *XPC* rs2228000 and cancer risk and referencing the similar publications \[[@B21],[@B22]\], the FPRP value of the positive results less than 0.2 under the prior probability level of 0.1 indicates a noteworthy outcome.

TSA {#sec2-6}
---

We also performed the TSA test to evaluate whether further research was needed, referring to some similar publications \[[@B23]\]. For the TSA parameter, a type I error probability of 5%, a statistical test power of 80%, and a low bias-based risk ratio reduction were established. Trial Sequential Analysis Viewer software (<http://www.ctu.dk/tsa/>) was utilized.

Results {#sec3}
=======

Identification of eligible studies {#sec3-1}
----------------------------------

In total, we obtained 1186 potential eligible articles \[PubMed (*n*=266), Embase \[*n*=687\], CNKI (*n*=28), and WOS (*n*=205)\] and then ruled out another 412 duplicates and 646 improper articles according to our exclusion criteria (detailed information listed in [Figure 1](#F1){ref-type="fig"}). Furthermore, we excluded 64 articles due to the question of 'lack of specific data or normal group', 'not in line with HWE' or 'cohort'. Finally, we identified a total of 71 eligible case--control studies from the 64 retrieved articles \[[@B1],[@B2],[@B4],[@B10],[@B11],[@B27]\] for pooling analysis. We summarized some basic information in [Table 1](#T1){ref-type="table"} and presented the flow chart in [Figure 1](#F1){ref-type="fig"}. All the genotypic distribution of the control group in all studies followed the principle of HWE. Although the NOS scores in all studies were larger than 5 (Supplementary Table S2), the risk-of-bias scores of nine articles (Supplementary Table S3) were less than 9.

![Selection process of eligible case--control studies\
 ](bsr-39-bsr20192452-g1){#F1}

###### Basic information of the studies included in the meta-analysis

  First author     Year        Country          Race        Cases   Cancer type   Control   Control source       Genotyping assay                       
  ---------------- ----------- ---------------- ----------- ------- ------------- --------- -------------------- ------------------ ----- ----- ------- -----------------------------
  **Al-Qadoori**   **2019**    Iraq             Asian       37      23            2         Bladder cancer       31                 7     0     PB      Gene sequencing
  **An**           **2007**    U.S.A.           Caucasian   445     293           91        HNSCC                454                342   58    HB      PCR-RFLP
  **Bai**          **2007**    China            Asian       184     193           48        LAC                  446                456   88    HB      TaqMan
                               China            Asian       149     149           34        LSCC                 446                456   88    HB      TaqMan
                               China            Asian       31      25            8         SCLC                 446                456   88    HB      TaqMan
  **Broberg**      **2005**    Sweden           Caucasian   35      20            6         Bladder cancer       92                 55    8     PB      MassARRAY
  **Chen**         **2013**    China            Asian       45      60            26        Cervical cancer      101                118   38    HB      PCR-RFLP
  **de Verdier**   **2010**    Sweden           Caucasian   138     138           35        Bladder cancer       196                124   10    PB      PCR-RFLP
  **Doherty**      **2011**    U.S.A.           Mixed       411     257           49        Endometrial cancer   384                278   61    PB      PCR-RFLP/SNaPshot
  **Dong**         **2008**    China            Asian       141     90            22        GCA                  272                282   58    PB      PCR-RFLP
  **Farnebo**      **2015**    Sweden           Caucasian   89      63            17        HNSCC                219                105   20    PB      PCR-RFLP
  **Figl**         **2010**    Spain/Germany    Caucasian   626     477           81        Melanoma             670                516   88    PB      TaqMan
  **Garcia**       **2006**    Spain            Caucasian   583     440           85        Bladder cancer       599                435   75    HB      SNP500Cancer
  **Guo**          **2008**    China            Asian       156     133           38        ESCC                 272                282   58    PB      PCR-RFLP
  **He**           **2016**    China            Asian       201     198           51        Breast cancer        228                174   28    PB      MassARRAY
  **He**           **2012**    China            Asian       104     90            16        Pancreatic cancer    106                85    22    PB      SNaPshot
  **Hu**           **2005**    China            Asian       124     171           25        Lung cancer          158                145   19    PB      PCR-PIRA
  **Hua**          **2016a**   China            Asian       432     531           178       CRC                  429                583   161   PB      TaqMan
  **Hua**          **2016b**   China            Asian       457     524           161       Gastric cancer       429                583   161   PB      TaqMan
  **Huang**        **2006**    U.S.A.           Mixed       397     261           31        CRC                  403                259   41    HB      SNP500Cancer
  **Ibarrola**     **2011**    Spain            Caucasian   323     227           49        Melanoma             198                158   23    PB/HB   MassARRAY
  **Jiao**         **2011**    China            Asian       127     177           30        GBC                  163                146   20    HB      PCR-RFLP
  **Jorgensen**    **2007**    U.S.A.           Caucasian   153     87            13        Breast cancer        157                104   14    PB      TaqMan
  **Kim**          **2002**    Korea            Asian       104     102           12        Lung cancer          77                 62    10    PB      PCR-RFLP
  **Lee**          **2005**    Korea            Asian       113     84            13        LSCC                 223                179   29    PB      PCR-RFLP
                               Korea            Asian       79      58            4         LAC                  223                179   29    PB      PCR-RFLP
                               Korea            Asian       39      28            6         SCLC                 223                179   29    PB      PCR-RFLP
  **Li**           **2006**    U.S.A.           Caucasian   338     214           50        Melanoma             318                248   37    HB      PCR-RFLP
  **Li**           **2014**    China            Asian       92      91            19        Gastric cancer       144                153   30    PB      PCR-RFLP
  **Li**           **2010**    China            Asian       163     248           89        HCC                  169                250   88    HB      TaqMan
  **Liang**        **2018**    China            Asian       98      89            18        Pancreatic cancer    116                90    24    HB      SNaPshot
  **Liu**          **2016**    China            Asian       444     351           96        Gastric cancer       424                408   95    HB      MassARRAY
  **Liu**          **2012**    China            Asian       242     294           64        Bladder cancer       272                285   52    PB      PCR-RFLP
  **Liu**          **2019**    China            Asian       178     159           54        Uterine leiomyoma    183                232   78    PB      Sequence Detection System
  **Long**         **2010**    China            Asian       170     156           35        GAA                  280                274   62    HB      TaqMan
  **McWilliams**   **2008**    U.S.A.           Mixed       246     182           29        Pancreatic cancer    339                211   32    HB      SNPstream or Pyrosequencing
  **Monroy**       **2011**    U.S.A.           Mixed       92      90            8         HL                   137                71    10    PB      MassARRAY
  **Na**           **2012**    China            Asian       213     124           23        Breast cancer        228                118   14    HB      MassARRAY
  **Nigam**        **2019**    China            Asian       22      22            26        Oral cancer          69                 145   83    PB      PCR-RFLP
  **Ozgoz**        **2019**    Turkey           Caucasian   57      38            7         Breast cancer        67                 26    7     PB      MassARRAY
  **Pan**          **2009**    U.S.A            Caucasian   228     129           26        Esophageal cancer    251                178   21    PB      TaqMan
  **Paszkowska**   **2015**    Poland           Caucasian   443     269           41        CRC                  548                563   177   PB      MassARRAY/Taqman
  **Paszkowska**   **2013**    Poland           Caucasian   245     240           34        Melanoma             548                563   177   PB      MassARRAY
  **Perez**        **2013**    U.S.A.           Caucasian   0       63            115       Breast cancer        21                 131   203   PB      TaqMan
  **Ravegnini**    **2016**    Italy            Caucasian   42      34            5         GIST                 90                 45    12    PB      TaqMan
  **Roberts**      **2011**    U.S.A.           Mixed       167     100           18        Breast cancer^1^     317                193   40    PB      MassARRAY
                               U.S.A.           Mixed       437     273           48        Breast cancer^2^     793                478   72    PB      MassARRAY
  **Sak**          **2006**    U.K.             Mixed       279     202           57        Bladder cancer       317                210   38    PB/HB   TaqMan
  **Sakoda**       **2012**    U.S.A.           Caucasian   401     299           43        Lung cancer          822                566   87    PB      GoldenGate/Taqman
  **Sankhwar**     **2016**    India            Asian       52      113           69        Bladder cancer       87                 112   59    PB      PCR-RFLP/gene sequencing
  **Santos**       **2013**    Portugal         Caucasian   47      55            4         Thyroid cancer       95                 98    19    HB      PCR-RFLP
  **Shen**         **2006**    U.S.A.           Caucasian   96      50            9         Breast cancer        91                 55    5     PB      TaqMan
  **Shen**         **2008**    U.S.A.           Mixed       614     385           62        Breast cancer        632                417   56    PB      Fluorescence polarization
  **Shen**         **2005**    China            Asian       56      47            13        Lung cancer          50                 47    13    PB      TaqMan
  **Slyskova**     **2012**    Czech Republic   Caucasian   36      24            9         CRC                  37                 24    3     PB      PCR-RFLP
  **Smith**        **2008**    U.S.A.           Caucasian   178     116           23        Breast cancer        211                161   29    PB      MassARRAY
                               U.S.A.           Others      44      7             1         Breast cancer        61                 14    0     PB      MassARRAY
  **Steck**        **2014**    U.S.A.           Others      175     51            2         CRC                  276                47    0     PB      MassARRAY
                               U.S.A.           Caucasian   177     104           22        CRC                  293                207   35    PB      MassARRAY
  **Tang**         **2011**    China            Asian       40      55            14        ALL                  80                 74    15    PB      MassARRAY
  **Weiss**        **2005**    U.S.A.           Mixed       211     129           31        Endometrial cancer   213                166   41    PB      SNaPshot
  **Wu**           **2011a**   China            Asian       172     195           52        CRC                  315                406   117   PB      PCR-RFLP
  **Wu**           **2011b**   China            Asian       65      86            22        Breast cancer        69                 85    16    PB      PCR-RFLP
  **Yang**         **2012**    China            Asian       197     322           99        Breast cancer        235                312   75    PB      PCR-RFLP
  **Yang**         **2008**    China            Asian       52      73            28        NPC                  76                 79    13    PB      PCR-RFLP
  **Zhao**         **2018**    China            Asian       46      35            8         Ovarian cancer       127                175   54    PB      TaqMan
  **Zheng**        **2016**    China            Asian       111     108           34        Neuroblastoma        205                250   76    PB      TaqMan
  **Zhou**         **2008**    China            Asian       103     78            27        Ovarian cancer       118                95    18    PB      PCR-RFLP
  **Zhu**          **2018**    China            Asian       64      59            22        Nneuroblastoma       205                250   76    PB      TaqMan
  **Zhu**          **2008**    China            Asian       110     60            18        ESCC                 83                 88    32    PB      PCR-RFLP
  **Zhu**          **2007**    U.S.A.           Caucasian   323     193           30        Bladder cancer       310                215   24    HB      TaqMan

Abbreviations: ALL, acute lymphoblastic leukemia; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; GAA, gastric antrum adenocarcinoma; GBC, primary gallbladder adenocarcinoma; GCA, gastric cardiac adenocarcinoma; GIST, gastrointestinal stromal tumour; HB, hospital-based; HCC, hepatocellular carcinoma; HL, Hodgkin lymphoma; HNSCC, head and neck squamous cell carcinoma; LAC, lung adenocarcinoma; LSCC, lung squamous cell carcinoma; NPC, nasopharyngeal cancer; PB, population-based; PCR, polymerase chain reaction; PIRA, primer-introduced restriction analysis; RFLP, restriction fragment length polymorphism; SCLC, Small cell lung carcinoma; SNP, single nucleotide polymorphism.

^1^ Premenopausal.

^2^ Postmenopausal.

Overall meta-analysis {#sec3-2}
---------------------

As shown in [Table 2](#T2){ref-type="table"}, our overall meta-analysis included a total of 71 studies with 26835 cases and 37069 controls. We observed high between-study heterogeneity ([Table 2](#T2){ref-type="table"}, all *I^2^* \> 50%, *P*~heterogeneity~\<0.001) and thus utilized the random-effect model for the pooling analysis. After pooling the different studies together, we only detected an increased risk of overall cancers under the TT vs. CC+CT model \[[Table 2](#T2){ref-type="table"}, *P~association~*=0.023, OR = 1.11, 95% CI = (1.01, 1.22)\] but not other models (all *P~association~*\>0.05). These results indicated that *XPC* rs2228000 does not seem to be statistically associated with susceptibility to cancer.

###### Meta-analysis of *XPC* rs2228000 and overall cancer risk

  Genetic model       Sample size   Association   Heterogeneity   Publication bias                             
  ------------------- ------------- ------------- --------------- ------------------ ------- --------- ------- -------
  **T vs. C**         71            26835/37069   0.218           1.03 (0.98,1.09)   72.2%   \<0.001   0.079   0.031
  **TT vs. CC**       71            26835/37069   0.090           1.10 (0.99,1.23)   64.6%   \<0.001   0.124   0.065
  **CT vs. CC**       71            26835/37069   0.588           0.98 (0.93,1.04)   59.1%   \<0.001   0.093   0.046
  **CT+TT vs. CC**    71            26835/37069   0.793           1.01 (0.95,1.07)   68.0%   \<0.001   0.069   0.023
  **TT vs. CC+ CT**   71            26835/37069   0.023           1.11 (1.01,1.22)   54.1%   \<0.001   0.493   0.230

Abbreviations: *P~association~*, *P*-value in the association test; *P~heterogeneity~*, *P*-value in the heterogeneity test; *P~Begg~*, *P*-value in Begg's test; *P~Egger~*, *P*-value in Egger's test.

Subgroup analysis {#sec3-3}
-----------------

Next, we performed a series of subgroup analyses by the factors of race, control source, country, article quality, and genotyping assay. As shown in [Table 3](#T3){ref-type="table"}, a total of 38 studies (12118 cases/18124 controls) were included for the subgroup analysis of 'Asian', while 22 studies with 9371 cases and 12338 controls were included for the 'Caucasian' subgroup. We did not observe a significant difference between cancer cases and negative controls under the most genetic models ([Table 3](#T3){ref-type="table"}, *P~association~*\>0.05), only apart from the Asian subgroup under the TT vs. CC+CT model \[*P~association~*=0.005, OR = 1.13, 95% CI = (1.04, 1.23)\]. Within the subgroup analysis by the factor or control source (PB/HB (population/hospital-based)), an increased risk of cancer was only detected in the 'HB' subgroup under TT vs. CC \[[Table 3](#T3){ref-type="table"}, *P~association~*=0.010, OR = 1.17, 95% CI = (1.04,1.32)\] and TT vs. CC+CT \[*P~association~*=0.006, OR = 1.18, 95% CI = (1.05, 1.32)\] models but not others (*P~association~*\>0.05). Similarly, we observed negative results in the majority of the subgroup analyses by country, article quality and genotyping assay (Supplementary Table S4). As examples, we presented the forest plots of the subgroup analysis data by the factor of race ([Figure 2](#F2){ref-type="fig"}), control source (Supplementary Figure S1), country (Supplementary Figure S2), article quality (Supplementary Figure S3), and genotyping assay (Supplementary Figure S4) under the T vs. C model.

![Subgroup analysis data by the factor of race under the T vs. C model\
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###### Subgroup analysis data by the factors of race and control source

  Genetic model       Subgroup    Sample size   Association           
  ------------------- ----------- ------------- ------------- ------- -------------------
  **T vs. C**         Asian       38            12118/18124   0.360   1.03 (0.97, 1.10)
                      Caucasian   22            9371/12338    0.572   1.03 (0.92, 1.16)
                      PB          52            17758/25317   0.447   1.03 (0.96, 1.10)
                      HB          17            7940/10808    0.109   1.04 (0.99, 1.09)
  **TT vs. CC**       Asian       38            12118/18124   0.091   1.11 (0.98, 1.25)
                      Caucasian   22            9371/12338    0.329   1.15 (0.87, 1.53)
                      PB          52            17758/25317   0.397   1.07 (0.92, 1.23)
                      HB          17            7940/10808    0.010   1.17 (1.04, 1.32)
  **CT vs. CC**       Asian       38            12118/18124   0.554   0.98 (0.90, 1.06)
                      Caucasian   22            9371/12338    0.483   0.96 (0.86, 1.07)
                      PB          52            17758/25317   0.612   0.98 (0.91, 1.06)
                      HB          17            7940/10808    0.857   0.99 (0.92, 1.07)
  **CT+TT vs. CC**    Asian       38            12118/18124   0.948   1.00 (0.92, 1.09)
                      Caucasian   22            9371/12338    0.905   0.99 (0.88, 1.12)
                      PB          52            17758/25317   0.965   1.00 (0.92, 1.09)
                      HB          17            7940/10808    0.581   1.02 (0.95, 1.09)
  **TT vs. CC+ CT**   Asian       38            12118/18124   0.005   1.13 (1.04, 1.23)
                      Caucasian   22            9371/12338    0.293   1.14 (0.89, 1.45)
                      PB          52            17758/25317   0.219   1.08 (0.96, 1.21)
                      HB          17            7940/10808    0.006   1.18 (1.05, 1.32)

Abbreviations: PB, population-based; *P~association~, P*-value in the association test.

Additionally, we performed a subgroup analysis using the specific cancer type. As shown in [Table 4](#T4){ref-type="table"}, in the subgroup of 'bladder cancer' with 3460 cases and 3613 controls, enhanced susceptibility was detected in bladder cancer cases under T vs. C \[[Table 4](#T4){ref-type="table"}, *P~association~*=0.004, OR = 1.25, 95% CI = (1.07, 1.45)\], TT vs. CC \[*P~association~*=0.001, OR = 1.68, 95% CI = (1.25, 2.26)\], CT+TT vs. CC \[*P~association~*=0.016, OR = 1.26, 95% CI = (1.04, 1.53)\], TT vs. CC+ CT \[*P~association~*= 0.001, OR = 1.49, 95% CI = (1.18, 1.90)\] compared with the negative controls. Additionally, there is an increased risk of breast cancer under T vs. C \[[Table 4](#T4){ref-type="table"}, *P~association~*=0.018, OR = 1.11, 95% CI = (1.02, 1.21)\], TT vs. CC \[*P~association~*=0.003, OR = 1.33, 95% CI = (1.10, 1.60)\], and TT vs. CC+ CT \[*P~association~*= 0.001, OR = 1.29, 95% CI = (1.12, 1.48)\]. Nevertheless, we observed a decreased risk of gastric cancer in the Chinese population under T vs. C \[[Table 4](#T4){ref-type="table"}, *P~association~*=0.020, OR = 0.92, 95% CI = (0.85, 0.99)\], CT vs. CC \[*P~association~*=0.001, OR = 0.83, 95% CI = (0.73, 0.93)\], CT+TT vs. CC \[*P~association~*=0.003, OR = 0.84, 95% CI = (0.76, 0.94)\]. The relevant forest plots under different genetic models are presented in [Figure 3](#F3){ref-type="fig"} (T vs. C), Supplementary Figure S5 (TT vs. CC), Supplementary Figure S6 (CT vs. CC), Supplementary Figure S7 (CT+TT vs. CC), and Supplementary Figure S8 (TT vs. CC+ CT).

![Subgroup analysis data by the factor of cancer type under the T vs. C model\
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###### Subgroup analysis data by the factors of specific cancer type

  Genetic model       Subgroup            Sample size   Association           
  ------------------- ------------------- ------------- ------------- ------- -------------------
  **T vs. C**         Bladder cancer      8             3460/3613     0.004   1.25 (1.07, 1.45)
                      Lung cancer         10            2642/6319     0.222   1.05 (0.97, 1.13)
                      Gastric cancer      5             2849/3655     0.020   0.92 (0.85, 0.99)
                      Melanoma            4             2904/3544     0.250   0.92 (0.81, 1.06)
                      Esophageal cancer   3             898/1265      0.210   0.83 (0.62, 1.11)
                      Breast cancer       13            4762/5937     0.018   1.11 (1.02, 1.21)
                      Pancreatic cancer   3             872/1025      0.380   1.07 (0.92, 1.23)
                      CRC                 7             3602/4924     0.776   0.97 (0.76, 1.23)
  **TT vs. CC**       Bladder cancer      8             3460/3613     0.001   1.68 (1.25, 2.26)
                      Lung cancer         10            2642/6319     0.252   1.11 (0.93, 1.34)
                      Gastric cancer      5             2849/3655     0.361   0.93 (0.78, 1.09)
                      Melanoma            4             2904/3544     0.697   0.90 (0.55, 1.50)
                      Esophageal cancer   3             898/1265      0.724   0.89 (0.46, 1.71)
                      Breast cancer       13            4762/5937     0.003   1.33 (1.10, 1.60)
                      Pancreatic cancer   3             872/1025      0.952   0.99 (0.69, 1.41)
                      CRC                 7             3602/4924     0.588   0.87 (0.52, 1.45)
  **CT vs. CC**       Bladder cancer      8             3460/3613     0.069   1.17 (0.99, 1.39)
                      Lung cancer         10            2642/6319     0.368   1.05 (0.95, 1.16)
                      Gastric cancer      5             2849/3655     0.001   0.83 (0.73, 0.93)
                      Melanoma            4             2904/3544     0.157   0.93 (0.83, 1.03)
                      Esophageal cancer   3             898/1265      0.013   0.73 (0.57, 0.94)
                      Breast cancer       13            4762/5937     0.418   1.04 (0.94, 1.16)
                      Pancreatic cancer   3             872/1025      0.128   1.16 (0.96, 1.40)
                      CRC                 7             3602/4924     0.405   0.91 (0.73, 1.13)
  **CT+TT vs. CC**    Bladder cancer      8             3460/3613     0.016   1.26 (1.04, 1.53)
                      Lung cancer         10            2642/6319     0.282   1.05 (0.96, 1.16)
                      Gastric cancer      5             2849/3655     0.003   0.84 (0.76, 0.94)
                      Melanoma            4             2904/3544     0.088   0.92 (0.83, 1.01)
                      Esophageal cancer   3             898/1265      0.065   0.74 (0.54, 1.02)
                      Breast cancer       13            4762/5937     0.175   1.08 (0.97, 1.21)
                      Pancreatic cancer   3             872/1025      0.182   1.13 (0.94, 1.36)
                      CRC                 7             3602/4924     0.563   0.93 (0.71, 1.20)
  **TT vs. CC+ CT**   Bladder cancer      8             3460/3613     0.001   1.49 (1.18, 1.90)
                      Lung cancer         10            2642/6319     0.293   1.10 (0.92, 1.32)
                      Gastric cancer      5             2849/3655     0.834   1.02 (0.87, 1.19)
                      Melanoma            4             2904/3544     0.826   0.94 (0.56, 1.59)
                      Esophageal cancer   3             898/1265      0.889   1.04 (0.61, 1.78)
                      Breast cancer       13            4762/5937     0.001   1.29 (1.12, 1.48)
                      Pancreatic cancer   3             872/1025      0.669   0.94 (0.66, 1.31)
                      CRC                 7             3602/4924     0.682   0.91 (0.58, 1.43)

Abbreviations: CRC, colorectal cancer; *P~association~, P*-value in the association test.

Moreover, we performed subgroup analysis data for different system cancers. As shown in Supplementary Table S5 and Figure S9 (forest plot data under the allelic model), we observed the same result in the subgroup of 'urinary system cancer' as the subgroup of 'bladder cancer'. There is a reduced cancer risk in the subgroup of 'reproductive system cancer' under the models of CT vs. CC \[*P~association~*=0.006, OR = 0.81, 95% CI = (0.70, 0.94)\] and CT+TT vs. CC \[*P~association~*=0.041, OR = 0.82, 95% CI = (0.68, 0.99)\] and an increased risk in the subgroup of 'head and neck cancer' under the TT vs. CC+CT \[*P~association~*=0.024, OR = 1.58, 95% CI = (1.06, 2.34)\]. However, no positive association was observed in other subgroups (Supplementary Table S5, *P~association~*\>0.05).

The above results indicated that the TT genotype of *XPC* rs2228000 seems to be related to a high risk of bladder and breast cancer, whereas the CT genotype is more likely to be associated with reduced susceptibility to gastric cancer in the Chinese population.

Publication bias/sensitivity {#sec3-4}
----------------------------

As shown in [Table 2](#T2){ref-type="table"}, we did not observe a notable publication bias among these comparisons, in that all the *P~Begg~*\>0.05, *P~Egger~*\>0.05 apart from the *P~Egger~*=0.031 (T vs. C), *P~Egger~*=0.046 (CT vs. CC), *P~Egger~*=0.023 (CT+TT vs. CC). [Figure 4](#F4){ref-type="fig"}A presents the publication bias plot of Egger's test under the T vs. C model. In addition, as shown in [Figure 4](#F4){ref-type="fig"}B (allelic model data as example), we also observed relatively stable pooling data through the performance of sensitivity analyses.

![Egger's test plot and the sensitivity analysis data under the T vs. C model\
(**A**) Egger's test; (**B**) sensitivity analysis data.](bsr-39-bsr20192452-g4){#F4}

FPRP/TSA {#sec3-5}
--------

An FPRP test was conducted to confirm the above positive findings for bladder, breast, and gastric cancers. The FPRP values of positive results at different prior probability levels are shown in Supplementary Table S6. We found that at a prior probability of 0.1 with an OR of 1.5, all the FPRP values were less than 0.2 (Supplementary Table S6, FPRP = 0.028, T vs. C; FPRP = 0.023, TT vs. CC; FPRP = 0.155, CT+TT vs. CC; FPRP = 0.022, TT vs. CC+ CT), indicating a noteworthy association between *XPC* rs2228000 and the risk of bladder cancer. Similar true positive associations were observed for breast and gastric cancer (Supplementary Table S6, all FPRP \< 0.02) at a prior probability of 0.1.

In addition, we also performed the TSA test to assess the robustness of our significant findings. As shown in the TSA data of breast cancer under the TT vs. CC+CT model ([Figure 5](#F5){ref-type="fig"}) and gastric cancer under the CT+TT vs. CC models (Supplementary Figure S10), we found that the cumulative number of participants (Z-curve) met the TSA monitoring boundary and required information size. With regard to the bladder cancer under the TT vs. CC+CT model (Supplementary Figure S11), the cumulative Z-curve crossed with the TSA monitoring boundary, even though it did not reach the required information size. These data therefore indicated the robustness of our conclusions.

![TSA for the association between *XPC* rs2228000 and the risk of breast cancer under the TT vs. CC+CT model\
 ](bsr-39-bsr20192452-g5){#F5}

Discussion {#sec4}
==========

There is a controversial conclusion regarding the genetic impacts of the *XPC* rs2228000 SNP in the risk of clinical cancer diseases in different publications. For example, *XPC* rs2228000 was reportedly related to susceptibility to bladder cancer cases in Iraq \[[@B27]\], Sweden \[[@B30]\], or India \[[@B67]\] but not the U.S.A. \[[@B85]\] or Spain \[[@B35]\]. Likewise, *XPC* rs2228000 was also significantly associated with the risk of breast cancer in a Chinese population \[[@B37],[@B78]\] but not Caucasians or African-Americans in the U.S.A. \[[@B72]\]. Although several meta-analyses of *XPC* rs2228000 and certain specific cancer types exist \[[@B86]\], differences in study enrolment, data extraction, analysis strategy, and result descriptions were observed. We thus conducted a meta-analysis and TSA for a comprehensive assessment regarding the genetic influence of the *XPC* rs2228000 in the risk of various types of cancer, including bladder cancer, lung cancer, gastric cancer, melanoma, esophageal cancer, breast cancer, pancreatic cancer, and colorectal cancer.

Only three prior meta-analyses with fewer than 15 studies in 2008 \[[@B12]\] and one meta-analysis with 33 articles in 2013 \[[@B15]\] were reported to detect the genetic association between *XPC* rs2228000 and overall cancer risk. In our study, we retrieved four databases (updated till September 2019) to include the potential publication for the pooling analysis. After employing our strict screen strategy, we finally included 64 eligible articles, which contained 71 case--control studies, for the overall meta-analysis and the following subgroup analyses by the factors of race, country, control source, article quality, genotyping assay, and cancer type. Five genetic models, including allelic, homozygotic, heterozygotic, dominant, and recessive models, were utilized. We excluded the improper studies according to the strict requirement of full genotype frequency data and the HWE principle. For instance, there are a total of 33 articles with 14877 cases and 17888 controls \[[@B1],[@B28],[@B30],[@B36],[@B39],[@B42],[@B44],[@B45],[@B47],[@B48],[@B50],[@B54],[@B60],[@B64],[@B68],[@B72],[@B75],[@B82],[@B93]\] for the prior meta-analysis of He et al. in 2013 \[[@B15]\]. In this study, we excluded two articles regarding bladder cancer \[[@B95]\] and cutaneous melanoma \[[@B94]\] because the genotype distribution in the control group is not in line with the HWE, and we added 32 other published articles \[[@B4],[@B10],[@B11],[@B27],[@B29],[@B33],[@B37],[@B38],[@B40],[@B41],[@B43],[@B46],[@B49],[@B51],[@B52],[@B57],[@B61],[@B67],[@B71],[@B73],[@B74],[@B80],[@B81],[@B83]\]. Our pooling data from eight case--control studies showed the genetic correlation between *XPC* rs2228000 and increased risk of bladder cancer under the allelic, homozygotic, heterozygotic, dominant, and recessive models, which is partly consistent with the positive data of He et al. (2013) \[[@B15]\] under the homozygotic and recessive models from four case--control studies. A similar result was obtained for breast cancer, even though four new case--control studies were added, compared with the pooling results of He et al. (2013) \[[@B15]\]. Moreover, we provided assessment evidence regarding the potential impact of *XPC* rs2228000 on the reduced susceptibility to gastric cancer in the Chinese population. Nevertheless, we did not detect a significant association between *XPC* rs2228000 and other types of cancer, such as lung cancer, melanoma, pancreatic cancer, or colorectal cancer.

In our study, we performed the FPRP test with a prior probability of 0.1 and an FPRP threshold of 0.2 to check whether the positive findings of breast, bladder, and gastric cancers are noteworthy, considering the potential presence of 'false positives'. After the FPRP estimation, the genetic association between *XPC* rs2228000 and the risk of bladder, breast, and gastric cancers risk remain significant at the prior probability level of 0.1. Furthermore, we observed the robustness of our conclusions through the performance of TSA test and sensitivity analyses and the absence of large publication bias by Begg's/Egger's test.

Despite these findings, some limitations to this research may still influence the statistical power of analyses of certain types of cancer. Although more than 70 case--control studies were enrolled in the overall meta-analysis, small sample sizes were still included in some subgroup analyses. For example, only two case--control studies \[[@B56],[@B74]\] were included for the subgroup of 'blood system cancer', while only two studies \[[@B81],[@B83]\] were enrolled for 'nervous system cancer'. Therefore, we still cannot rule out the possible genetic role played by *XPC* rs2228000 in the risk of cancers of the blood or nervous systems. A similar uncertainty also exists in the subgroup analysis of 'lung cancer', 'melanoma', 'esophageal cancer', 'pancreatic cancer' and 'CRC'.

We observed clear between-study heterogeneity, even if articles with low quality are removed. Regarding the available sample size, more factors, such as gender, age, environmental exposure, drinking/smoking status, tumor situations, characteristics, antiepileptic agents, or drug resistance, should be adjusted in future pooling analyses. It would be valuable to carry out an integrated analysis to evaluate the combined role of more *XPC* polymorphic loci (e.g., rs2228001, PAT^−/+^) in susceptibility to different types of cancer based on the available evidence.

Conclusions {#sec5}
===========

In general, the TT genotype of *XPC* rs2228000 may be linked to an increased risk of bladder and breast cancers, whereas the CT genotype is more likely to be associated with a reduced susceptibility to gastric cancer in the Chinese population. Considering the limitations of our study, we need to analyze more publications to verify the genetic impact of *XPC* rs2228000 in other types of cancer.
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